HAYWARD, Calif. — Impax Laboratories Inc. has entered a collaboration with Perrigo Co. on a generic topical medication.
Impax said Wednesday the development, manufacturing and commercialization agreement involves an "extended topical generic drug product" with "first to market potential."
"We are excited to expand our relationship with Perrigo on this product," Larry Hsu, president and chief executive officer Impax, said in a statement. "In just over two years, Impax has partnered with four different companies on 27 alternative dosage form products, with 18 of these either pending approval at the U.S. Food and Drug Administration or under development. We will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms."
The topical product and the terms of the agreement weren’t disclosed.
"This collaboration is yet another example of our long-term investment in development of products in the extended topical space," stated Perrigo chairman and CEO Joseph Papa. "We are pleased to be partnering with Impax on this opportunity to be first to market with this important new product, making quality health care more affordable for our customers as quickly as possible."
